Candriam Luxembourg S.C.A. Sells 45,000 Shares of NewLink Genetics Corp (NLNK)

Candriam Luxembourg S.C.A. lowered its stake in NewLink Genetics Corp (NASDAQ:NLNK) by 15.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 248,000 shares of the biotechnology company’s stock after selling 45,000 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.67% of NewLink Genetics worth $593,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC acquired a new position in shares of NewLink Genetics in the second quarter valued at approximately $133,000. Russell Investments Group Ltd. acquired a new position in shares of NewLink Genetics in the third quarter valued at approximately $219,000. Pennsylvania Trust Co increased its holdings in shares of NewLink Genetics by 35.8% in the third quarter. Pennsylvania Trust Co now owns 112,719 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 29,719 shares during the period. Acadian Asset Management LLC increased its holdings in shares of NewLink Genetics by 11.9% in the third quarter. Acadian Asset Management LLC now owns 289,092 shares of the biotechnology company’s stock valued at $691,000 after purchasing an additional 30,634 shares during the period. Finally, Alambic Investment Management L.P. increased its holdings in shares of NewLink Genetics by 593.8% in the second quarter. Alambic Investment Management L.P. now owns 366,995 shares of the biotechnology company’s stock valued at $1,747,000 after purchasing an additional 314,095 shares during the period. 44.87% of the stock is currently owned by institutional investors and hedge funds.

NewLink Genetics stock opened at $1.94 on Monday. NewLink Genetics Corp has a 1-year low of $1.80 and a 1-year high of $10.41. The company has a market capitalization of $72.22 million, a P/E ratio of -0.84 and a beta of 1.55.

NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.22. NewLink Genetics had a negative return on equity of 42.27% and a negative net margin of 253.52%. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $2.10 million. As a group, research analysts anticipate that NewLink Genetics Corp will post -1.48 EPS for the current year.

A number of research firms have recently issued reports on NLNK. Stifel Nicolaus lowered NewLink Genetics from a “buy” rating to a “hold” rating and dropped their target price for the company from $8.00 to $4.00 in a report on Wednesday, August 1st. Zacks Investment Research upgraded NewLink Genetics from a “hold” rating to a “strong-buy” rating and set a $2.50 price target on the stock in a research note on Wednesday, November 7th. Finally, Bank of America decreased their price target on NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, November 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $4.75.

ILLEGAL ACTIVITY NOTICE: “Candriam Luxembourg S.C.A. Sells 45,000 Shares of NewLink Genetics Corp (NLNK)” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/26/candriam-luxembourg-s-c-a-sells-45000-shares-of-newlink-genetics-corp-nlnk.html.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Featured Story: How to Invest in the Dividend Aristocrat Index

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply